NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

The company plans to use the new capital to validate its Idylla platform and to continue developing a range of assays, most of them oncology-related.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.